94E Stock Overview
A clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Zura Bio Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.12 |
| 52 Week High | US$9.90 |
| 52 Week Low | US$1.73 |
| Beta | 0.25 |
| 11 Month Change | -39.42% |
| 3 Month Change | 52.94% |
| 1 Year Change | -68.48% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -63.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| 94E | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.8% | 4.9% | 0.9% |
| 1Y | -68.5% | -16.6% | 4.2% |
Return vs Industry: 94E underperformed the German Biotechs industry which returned -19.3% over the past year.
Return vs Market: 94E underperformed the German Market which returned 3.1% over the past year.
Price Volatility
| 94E volatility | |
|---|---|
| 94E Average Weekly Movement | 20.4% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 94E's share price has been volatile over the past 3 months.
Volatility Over Time: 94E's weekly volatility has increased from 14% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 15 | Rob Lisicki | zurabio.com |
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Zura Bio Limited Fundamentals Summary
| 94E fundamental statistics | |
|---|---|
| Market cap | €198.68m |
| Earnings (TTM) | -€56.09m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.5x
P/E RatioIs 94E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 94E income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$60.18m |
| Earnings | -US$60.18m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.97 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 94E perform over the long term?
See historical performance and comparison